by admin | May 5, 2020 | Press
The fourth-most mentioned fear (at 14%) was a resurgence or a spike in infections after restrictions are lifted. Much about the SARS-CoV-2 virus is still being discovered. “Our biggest fear regarding the pandemic is that there will be future waves of outbreaks until...
by admin | Mar 24, 2020 | Press
SAN DIEGO, March 24, 2020 (GLOBE NEWSWIRE) — AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and cannabinoid research, announced today that its...
by admin | Mar 18, 2020 | Press
NEW YORK, March 18, 2020 (GLOBE NEWSWIRE) — AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and cannabinoid research, announced today that the Company has...
by admin | Mar 13, 2020 | Press
Sapphire Biotech, a facet of Axim, has partnered with ASU by providing licensing technology to support research that strives to inhibit one of the enzymes that facilitates the spread of cancer in the body. Sapphire Biotech will work with ASU by conducting preclinical...
by admin | Feb 21, 2020 | Press
In January 2020, Sapphire Biotech, Inc., acquiree of AXIM Biotechnologies, signed an agreement with Skysong Innovations establishing license rights to pharmaceutical materials and methods for cancer treatment. Such a development is a win in the fight against cancer...
by admin | Jan 22, 2020 | Press
SAN DIEGO, Jan. 22, 2020 (GLOBE NEWSWIRE) — AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological research, announced today that its acquiree Sapphire Biotech,...
